ReShape Lifesciences Inc.

NasdaqCM RSLS

ReShape Lifesciences Inc. Price to Book Ratio (P/B) on January 14, 2025: 0.87

ReShape Lifesciences Inc. Price to Book Ratio (P/B) is 0.87 on January 14, 2025, a -34.55% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • ReShape Lifesciences Inc. 52-week high Price to Book Ratio (P/B) is 2.24 on July 16, 2024, which is 158.28% above the current Price to Book Ratio (P/B).
  • ReShape Lifesciences Inc. 52-week low Price to Book Ratio (P/B) is 0.77 on December 23, 2024, which is -10.75% below the current Price to Book Ratio (P/B).
  • ReShape Lifesciences Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 1.22.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Loading...
NasdaqCM: RSLS

ReShape Lifesciences Inc.

CEO Mr. Paul F. Hickey
IPO Date Oct. 6, 2016
Location United States
Headquarters 1001 Calle Amanecer
Employees 29
Sector Health Care
Industries
Description

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Similar companies

TNON

Tenon Medical, Inc.

USD 1.67

-3.47%

NUWE

Nuwellis, Inc.

USD 1.05

3.96%

NURO

NeuroMetrix, Inc.

USD 3.98

-0.75%

HSCS

Heart Test Laboratories, Inc.

USD 3.26

1.24%

SINT

Sintx Technologies, Inc.

USD 3.21

-4.46%

StockViz Staff

January 15, 2025

Any question? Send us an email